Serum Uric Acid Levels and Cerebral Microbleeds in Patients with Acute Ischemic Stroke

Wi-Sun Ryu¹,², Chi Kyung Kim¹,², Beom Joon Kim³, Seung-Hoon Lee¹,²

¹ Department of Neurology, Seoul National University Hospital, Seoul, Republic of Korea, ² Clinical Research Center for Stroke, Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea, ³ Department of Neurology, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea

Abstract

Unlike experimental studies indicating a neuroprotective property of uric acid, clinical studies have shown that elevated levels of uric acid are associated with a risk of ischemic stroke. However, the association of uric acid with cerebral hemorrhage has seldom been tested. We aimed to elucidate the association between uric acid and cerebral microbleeds (CMBs), a hemorrhage-prone cerebral microangiopathy. Seven hundred twenty-four patients with ischemic stroke who were consecutively admitted to our hospital were included in this study. We collected demographic, clinical, and laboratory data, including uric acid level, and examined the presence of CMBs using T2*-weighted gradient-echo MRI. We used logistic regression analysis to examine an independent association between uric acid and CMBs. Two-hundred twenty-six patients had CMBs (31.2%). After adjusting for possible confounders, elevated uric acid was independently associated with the presence of CMBs (the highest quartile vs. the lowest quartile, adjusted odd ratio [OR], 1.98; 95% confidence interval [CI], 1.16–3.39). This association retained in patients with deep or infratentorial CMBs (with or without lobar CMBs) but not among those with lobar CMBs. In addition, this association was robust among patients with hypertension (the highest quartile vs. the lowest quartile, adjusted OR, 2.74; 95% CI, 1.43–5.24). In contrast, we did not find the association in patients without hypertension. We demonstrated that serum uric acid is independently associated with the presence of CMBs. In particular, the relation between uric acid and CMBs was robust in hypertensive patients.

Citation: Ryu W-S, Kim CK, Kim BJ, Lee S-H (2013) Serum Uric Acid Levels and Cerebral Microbleeds in Patients with Acute Ischemic Stroke. PLoS ONE 8(1): e55210. doi:10.1371/journal.pone.0055210

Editor: Alice Y. W. Chang, Kaohsiung Chang Gung Memorial Hospital, Taiwan
Received August 9, 2012; Accepted December 22, 2012; Published January 25, 2013

Copyright: © 2013 Ryu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by grants of the Korea Health 21 R&D Project, Ministry of Health and Welfare (A111014), and by Basic Science Research Program through the National Research Foundation of Korea funded by Ministry of Education, Science, and Technology (2011-0026315). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Uric acid has been reported to exert neuroprotective effects by acting as a free radical scavenger [1]. Uric acid is a strong reducing agent and a potent antioxidant, and approximately one half of the antioxidant capacity of plasma comes from uric acid [2]. In an animal stroke model, the administration of uric acid resulted in a better outcome [3]. In contrast, large population-based studies have indicated that increased levels of uric acid are an independent risk factor for cardiovascular disease and stroke [4,5]. Elevated uric acid levels have been associated with a poor outcome in patients with heart failure [6], coronary heart disease [7], and stroke [8]. The precise role of uric acid in vascular disease is still a matter of ongoing controversy.

Subclinical vascular brain lesions are easily visualized by brain magnetic resonance image (MRI). The lesion findings are generally classified into ischemia-prone and hemorrhage-prone microangiopathy [9]. The former has been referred as white matter lesions (WMLs) or leukoaraiosis seen on T2-weighted or fluid-attenuated inversion recovery MRI [10]. The latter was recently identified, and has been frequently called cerebral microbleeds (CMBs). Because the nature of these lesions is small bleeding from the advanced lipohyalinized arterioles due to chronic hypertension, the CMBs have been understood to be a harbinger of intracerebral hemorrhage (ICH) [11–13].

A recent report has indicated that increased levels of uric acid are positively associated with large WMLs [4], but there has been no study on the relationship between uric acid and CMBs. Given a proven association between uric acid and vascular disease, we hypothesized that levels of uric acid are related with the presence of CMBs. In this study, we sought to find an association between levels of uric acid and presence of CMBs in a large-sized consecutive series of ischemic stroke patients.

Methods

Study Population

Between March 2003 and September 2006, we consecutively enrolled acute ischemic stroke patients aged 50 years or older who were admitted to our hospital within 7 days after symptom onset (n = 834). We excluded patients who did not undergo gradient-echo MR imaging for various reasons (n = 95) or lacked essential medical information (n = 15). The final sample size was 724 stroke patients recruited for this study. The study was carried out in accordance with the Declaration of Helsinki and was approved by the Seoul National University Hospital institutional board review with waiver of consent.
Blood Pressure Measurement and Data Collection

We recorded demographic data, conventional risk factors, and important laboratory data for all subjects. Conventional risk factors included hypertension, diabetes, hypercholesterolemia, heart diseases, and smoking history. Blood pressure was measured on the discharge day. After a 5-minute period of supine rest, blood pressures were measured by auscultation in the dominant arm using a random-zero sphygmomanometer on 2 occasions separated by 2 minutes and averaged. If the dominant arm was affected by stroke, we used the non-dominant arm for a blood pressure measurement. Hypertension was diagnosed as present if the patients exhibited a systolic blood pressure >140 mm Hg or a diastolic blood pressure >90 mm Hg, or had a history of diagnosis of hypertension and anti-hypertensive medications. Only 4.1% patients had a blood pressure measurement within 7 days after symptom onset. Diabetes was present if subjects exhibited a fasting glucose level >7.0 mmol/L (126 mg/dL) or had a history of diabetes diagnosis and anti-diabetic medications. A diagnosis of hypercholesterolemia was made for patients with a history of using cholesterol-lowering agents or who had a fasting serum total cholesterol level >6.2 mmol/L (240 mg/dL) on admission. Heart diseases included atrial fibrillation, myocardial infarction, and valvular heart disease. Smoking was coded as positive if the patient was a current smoker or an ex-smoker who had quit smoking within five years prior to stroke onset. Fasting blood samples were drawn within 24 h of admission, and examined for uric acid and a standard battery of biochemical and hematological tests. Uric acid level was measured by uric acid oxidase reagent on a Dax analyzer [Bayer-Technichon] [14]. Glomerular filtration rate was calculated using a 4-item Modification of Diet in Renal Disease formula [15].

Brain MR Imaging

Brain MR imaging was performed on a 1.5 T superconducting magnet system (GE Medical System, Milwaukee, WI, USA). T2*-weighted gradient-echo MR imaging data were obtained in the axial plane using the following parameters: repetition time/echo time, 500/15 msec; flip angle, 26°; and matrix size, 256×192. CMBs were characterized as well-defined focal areas of dark signal intensity measuring less than 5 mm in diameter with blooming artifact on gradient-echo MR imaging. We did not include lesions that were within the subarachnoid space and areas of symmetric hypointensity of the globus pallidus, which were likely to represent adjacent pial blood vessels and calcification, respectively. CMBs were categorized in one of three locations: lobar (cortical gray and subcortical or periventricular white matter), deep (deep gray matter: basal ganglia and thalamus, and the white matter of the corpus callosum, internal, external, and extreme capsule), and infratentorial (brainstem and cerebellum) [16]. Two stroke neurologists (B.J. Kim and C.K. Kim), blinded to the clinical characteristics, reviewed the images.

Fluid-attenuated inversion recovery MR imaging was performed to detect WMIs using the following parameters: repetition time/echo time, 8300/96 ms; inversion time, 2100 ms; flip angle, 26°; and matrix size, 236×192. The WMIs were classified into four grades: grade 0, no abnormality or minimal periventricular signal hyperintensities in the form of caps confined exclusively to the anterior horns or rims lining the ventricles; grade 1,
may have a statistical interaction. To assess the different impacts of an independent association between levels of uric acid and CMBs, we further included WMLs as a covariate to examine glomerular filtration rate, body mass index, smoking, and total previous stroke, heart disease, previous antithrombotic use, diabetes, and cholesterol. We selected covariates that are related with the presence of CMBs in univariate analysis with p<0.10. In addition, we also incorporated predefined potential confounders that are acknowledged to be associated with CMBs in the prior studies. The covariates included age, sex, hypertension, diabetes, previous stroke, heart disease, previous antithrombotic use, glomerular filtration rate, body mass index, smoking, and total cholesterol. We further included WMLs as a covariate to examine an independent association between levels of uric acid and CMBs, because CMBs and WMLs are closely related pathologically, and may have a statistical interaction. To assess the different impacts of uric acid on CMBs by location, we repeated the analyses in separate groups: strictly lobar CMBs and deep or infratentorial CMBs (with or without lobar CMBs). Considering the relation between uric acid and hypertension, we also examined whether the association between CMBs and uric acid is dissimilar by the presence of hypertension. For the sensitivity analysis, we reran the multivariable model after excluding the patients with blood pressure measurement <7 days after symptom onset. A two-tailed p value of <0.05 was considered to be statistically significant. Data analyses were performed using SPSS ver.12.0 (SPSS Inc., Chicago, IL, USA).

Results

The uric acid level ranged from 0.06 to 0.71 mmol/L (mean, 0.30±0.10 mmol/L). Baseline characteristics according to the presence of CMBs are elaborated in Table 1. Patients with CMBs were more likely to be older and to have hypertension, a history of previous stroke, higher WMLs grade, and higher systolic blood pressure compared with those without CMBs. Patients with higher quartiles of uric acid were likely to have hypertension, hypercholesterolemia, and heart disease (Table 2). The grade of WMLs tended to increase with increasing quartiles, albeit not significant. The prevalence of CMBs increased with increasing quartiles (Table 3). After adjustment for age and sex, the third and the fourth quartiles of uric acid were significantly associated with the presence of CMBs. After adjusting for other potential confounders, the adjusted odds ratio of CMBs for the third and the fourth quartiles were 1.78 (95% confidence interval [CI], 1.06–2.98) and

Table 2. Baseline Characteristics of Patients across Sex-Specific Quartile of Uric Acid.

| Uric Acid (N = 724) | Quartile 1 (n = 186) | Quartile 2 (n = 183) | Quartile 3 (n = 170) | Quartile 4 (n = 185) | p |
|---------------------|---------------------|---------------------|---------------------|---------------------|---|
| Presence of CMBs    | 23.1%               | 25.7%               | 35.9%               | 40.5%               | <0.01|
| Age                 | 67.8±9.0            | 66.4±9.3            | 67.7±8.9            | 67.7±9.0            | 0.44|
| Sex, men            | 60.8%               | 65.0%               | 64.1%               | 67.0%               | 0.65|
| Hypertension        | 56.5%               | 60.7%               | 75.9%               | 80.5%               | <0.01|
| Diabetes            | 30.6%               | 38.2%               | 37.2%               | 30.8%               | 0.27|
| Hypercholesterolemia| 11.8%               | 14.8%               | 17.6%               | 22.7%               | 0.04|
| Previous stroke     | 23.7%               | 17.5%               | 21.8%               | 22.7%               | 0.49|
| Heart disease       | 22.6%               | 31.7%               | 20.0%               | 40.0%               | <0.01|
| Smoking (current or quit <5 years) | 23.1% | 34.4% | 26.5% | 26.5% | 0.10|
| BMI (kg/m²)         | 23.2±3.0            | 24.2±3.6            | 24.3±3.0            | 24.2±3.0            | <0.01|
| Previous use of antithrombotic | 13.1% | 15.4% | 11.4% | 13.2% | 0.75|
| Systolic blood pressure, mmHg | 140±25 | 139±22 | 144±25 | 141±24 | 0.19|
| Diastolic blood pressure, mmHg | 83±14 | 84±14 | 85±17 | 86±15 | 0.17|
| Total cholesterol, mmol/L | 4.63±0.96 | 4.62±0.88 | 4.83±0.94 | 4.79±1.16 | 0.09|
| Glucose, mmol/L     | 6.83±2.66           | 7.05±2.78           | 6.48±2.29           | 6.43±2.18           | 0.07|
| GFR (mL/min/1.73 m²) | 66.4±18.7           | 68.7±23.9           | 69.8±18.9           | 68.1±19.8           | 0.50|
| White matter lesion grade | 0.18 | 0.3 | 0.3 | 0.3 | 0.3 |

Data are presented as means±SD or percentages.
CMBs, cerebral microbleeds; BMI, body-mass index.
doi:10.1371/journal.pone.0055210.t002
Although adjustment for WMLs moderately attenuated the association, the patients in the highest quartile of uric acid had a 2-fold increased risk of CMBs compared with those in the lowest quartile. In addition, age (per one year, odds ratio [OR] 1.04, 95% CI 1.01–1.07), previous history of stroke (OR 2.00, 95% CI 1.16–3.43), and hypertension (OR 2.28, 95% CI 1.43–3.65) were independently associated with the presence of CMBs.

When we divided CMBs into strictly lobar and deep or infratentorial (with or without lobar CMBs), the association between uric acid quartiles and CMBs was significant in the deep or infratentorial CMBs group but not in the strictly lobar CMBs group (Table 3). In fully adjusted model, ORs of deep or infratentorial CMBs for the fourth quartile of uric acid was 2.21 (95% CI, 1.22–4.00). We found a significant relationship of uric acid with CMBs in patients with hypertension but not among those without hypertension.

1.93 (95% CI, 1.15–3.32). Although adjustment for WMLs moderately attenuated the association, the patients in the highest quartile of uric acid had a 2-fold increased risk of CMBs compared with those in the lowest quartile. In addition, age (per one year, odds ratio [OR] 1.04, 95% CI 1.01–1.07), previous history of stroke (OR 2.00, 95% CI 1.16–3.43), and hypertension (OR 2.28, 95% CI 1.43–3.65) were independently associated with the presence of CMBs.

|                  | Patients with CMBs, % | Age and sex adjusted OR (95% CI) | Model 1 adjusted OR (95% CI) | Model 2 adjusted OR (95% CI) |
|------------------|-----------------------|----------------------------------|------------------------------|-------------------------------|
| **Any (n = 226)**|                       |                                  |                              |                               |
| Quartile 1       | 23.1%                 | Reference                        | Reference                    | Reference                     |
| Quartile 2       | 25.7%                 | 1.19 (0.74–1.92)                 | 1.05 (0.60–1.82)             | 1.07 (0.60–1.91)             |
| Quartile 3       | 35.9%                 | 1.89 (1.19–3.01)                 | 1.78 (1.06–2.98)             | 1.65 (0.96–2.83)             |
| Quartile 4       | 40.5%                 | 2.33 (1.48–3.66)                 | 1.93 (1.15–3.23)             | 1.98 (1.16–3.39)             |
| P for trend      | 0.001                 | 0.017                            | 0.033                        |                               |
| **Strictly Lobar (n = 46)** |               |                                  |                              |                               |
| Quartile 1       | 5.9%                  | Reference                        | Reference                    | Reference                     |
| Quartile 2       | 8.2%                  | 1.43 (0.64–3.21)                 | 1.42 (0.59–3.42)             | 1.44 (0.60–3.50)             |
| Quartile 3       | 5.3%                  | 0.89 (0.36–2.20)                 | 1.13 (0.44–2.93)             | 1.16 (0.45–3.00)             |
| Quartile 4       | 5.9%                  | 1.00 (0.42–2.38)                 | 1.00 (0.39–2.58)             | 1.01 (0.39–2.61)             |
| P for trend      | 0.676                 | 0.845                            | 0.826                        |                               |
| **Deep or infratentorial* (n = 180)** |               |                                  |                              |                               |
| Quartile 1       | 17.2%                 | Reference                        | Reference                    | Reference                     |
| Quartile 2       | 17.5%                 | 1.06 (0.62–1.82)                 | 0.83 (0.43–1.60)             | 0.81 (0.40–1.62)             |
| Quartile 3       | 30.6%                 | 2.16 (1.31–3.58)                 | 1.85 (1.05–3.27)             | 1.67 (0.92–3.03)             |
| Quartile 4       | 34.6%                 | 2.62 (1.61–4.28)                 | 2.14 (1.22–3.77)             | 2.21 (1.22–4.00)             |
| P for trend      | <0.001                | 0.003                            | 0.005                        |                               |

Model 1 is adjusted for age, sex, hypertension, diabetes, previous stroke, heart disease, previous antithrombotic use, glomerular filtration rate, body mass index, smoking and total cholesterol; model 2, adjusted for model 1 plus white matter lesion.

*with or without lobar cerebral microbleeds.

doi:10.1371/journal.pone.0055210.t003

When we divided CMBs into strictly lobar and deep or infratentorial (with or without lobar CMBs), the association between uric acid quartiles and CMBs was significant in the deep or infratentorial CMBs group but not in the strictly lobar CMBs group (Table 3). In fully adjusted model, ORs of deep or infratentorial CMBs for the fourth quartile of uric acid was 2.21 (95% CI, 1.22–4.00). We found a significant relationship of uric acid with CMBs in patients with hypertension but not among those without hypertension.

|                  | Patients with CMBs, % | Age and sex adjusted OR (95% CI) | Model 1 adjusted OR (95% CI) | Model 2 adjusted OR (95% CI) |
|------------------|-----------------------|----------------------------------|------------------------------|-------------------------------|
| **Without hypertension (n = 226)** |                   |                                  |                              |                               |
| Quartile 1       | 17.3%                 | Reference                        | Reference                    | Reference                     |
| Quartile 2       | 19.4%                 | 1.24 (0.54–2.86)                 | 0.88 (0.30–2.57)             | 0.78 (0.26–2.39)             |
| Quartile 3       | 19.5%                 | 1.19 (0.45–3.14)                 | 1.33 (0.45–3.99)             | 1.22 (0.39–2.78)             |
| Quartile 4       | 19.4%                 | 1.17 (0.42–3.23)                 | 0.82 (0.24–2.80)             | 0.73 (0.20–2.65)             |
| P for trend      | 0.963                 | 0.882                            | 0.863                        |                               |
| **With hypertension (n = 494)** |                   |                                  |                              |                               |
| Quartile 1       | 27.6%                 | Reference                        | Reference                    | Reference                     |
| Quartile 2       | 29.7%                 | 1.11 (0.62–2.02)                 | 0.99 (0.49–2.02)             | 1.06 (0.50–2.21)             |
| Quartile 3       | 41.1%                 | 1.87 (1.07–3.26)                 | 2.04 (1.08–3.88)             | 1.92 (1.05–3.70)             |
| Quartile 4       | 45.6%                 | 2.27 (1.32–3.88)                 | 2.59 (1.39–4.82)             | 2.74 (1.43–5.24)             |
| P for trend      | 0.005                 | 0.002                            | 0.004                        |                               |

Model 1 is adjusted for age, sex, diabetes, previous stroke, heart disease, previous antithrombotic use, body mass index, glomerular filtration rate, smoking, and total cholesterol; model 2, adjusted for model 1 plus white matter lesion.

doi:10.1371/journal.pone.0055210.t004
those without hypertension. In patients with hypertension, the third and the fourth quartiles of uric acid were independently associated with CMBs in fully adjusted model (adjusted ORs 1.92 and 2.74, table 4).

Thirty patients had a blood pressure measurement within 7 days after symptom onset because of in-hospital death (n = 21) and early discharge due to mild symptoms (n = 9). After exclusion of these patients, the association between CMBs and uric acid essentially unchanged. In fully adjusted model, the odds ratio of CMBs for the third and the fourth quartiles were 1.77 (95% confidence interval [CI], 1.03–2.96) and 1.94 (95% CI, 1.18–3.41).

Discussion

We found that uric acid is independently associated with the presence of CMBs in patients with acute ischemic stroke. The association sustained in patients with deep or infratentorial CMBs but not among those with strictly lobar CMBs. Furthermore, this association was strengthened in patients with hypertension. In patients without hypertension, however, uric acid was not related to the presence of CMBs.

CMBs are divided into two subtypes according to its main pathology, hypertensive microangiopathy and cerebral amyloid angiopathy [9]. CMBs related with hypertensive predominantly located at deep brain structure, basal ganglia, thalamus, and brain stem. In contrast, CMBs related with cerebral amyloid angiopathy are commonly found in subcortical area. For hypertensive CMBs, chronic hypertension is the most consistent and important risk factor [16,18]. Moreover, hypertensive CMBs have been associated with hypertensive organ damage, including left ventricular mass index [19], hypertensive retinopathy [20], and chronic kidney disease [21]. Several pathophysiological mechanisms linking uric acid to hypertensive organ damage at the cellular and tissue levels have been proposed, including a proliferation of vascular smooth muscle cells [22], stimulation of the inflammatory pathway [23], and possible prothrombotic effects mediated by platelet activation [24]. Furthermore, uric acid has proven to be an excellent marker for tissue ischemia and endothelial dysfunction [25,26], and it has been shown to play a role in the evolution of atherosclerotic lesions [27]. Analyses based on the Framingham Heart Study have shown that serum uric acid was an independent predictor of the presence and progression of hypertension [28]. Taken together, our results that uric acid is associated with deep or infratentorial CMBs but not with lobar CMBs and that the relationship between uric acid and CMBs was found in patients with hypertension but not in those without hypertension suggest that CMBs may be the brain phenotype of hypertensive organ damage and uric acid may in part mediate the injury process.

Ample evidence has indicated that CMBs are closely related to ICH [11,29]. Earlier studies have suggested that CMBs could be a representative marker of ICH based on reports that the risk factors for CMBs are similar to those for ICH and on the common histopathologic findings for both types of lesions [30,31]. Furthermore, recent reports have strongly corroborated the association between CMBs and ICH: (1) Regional association between CBMs and ICH [13]; (2) Association between CBMs and volume, occurrence, and recurrence of ICH [32,33]; (3) Relationship of CBMs with warfarin-related hemorrhage [11]; and (4) Association between CBMs and the hemorrhagic transformation after thrombolysis [34]. Hence, it seems plausible to assume that increased levels of uric acid might increase a risk of ICH.

In the present study, we found no significant association between uric acid and WMLs. This is supposedly caused by a crude white matter lesion grading system. In a previous study demonstrating a positive association between uric acid and WMLs, the WMLs were calculated in a quantitative manner [4]. However, we graded WMLs according to the system described by Fazekas [35].

Several limitations of our study deserve comment. First, it is well known that patients with acute stroke, even without a history of previous hypertension, often have a high blood pressure [36]. Previous studies have shown that blood pressure gradually declines and reaches baseline level at 7 days after symptom onset [36,37]. Although only 4.1% patients in our study had a blood pressure measurement within 7 days after symptom onset and the association between uric acid and CBMs sustained after excluding these patients, we could not completely rule out the possibility that a blood pressure variation caused by acute stroke has influenced out results. Second, our study included patients with acute ischemic stroke. The presence of CBMs could therefore be affected by acute ischemic stroke [38]. However, a previous report have revealed that a rapid appearance of CMBs after ischemic stroke was related with only the presence of baseline CBMs and white matter lesion volumes. Thus, we believe that this bias had little impact on our results [38]. Third, there is a possibility of selection bias. To minimize the likelihood of bias, we studied all consecutive patients, and uric acid was measured as a part of the routine work-up. Fourth, we were unable to obtain the information as to whether the patients had used uric acid-lowering agents. After a meticulous search in the medical records, we found some patients who were taking uric acid-lowering agents. However, this investigation raised a possibility of an additional bias because we were unable to inspect the entire sample due to the retrospective nature of our study. Finally, our hypothesis-generating cross-sectional study was unable to provide a direct causal relationship between uric acid and CMBs.

Although it is indeterminate whether hyperuricemia is an independent risk factor requiring treatment, or if it is an innocent bystander in proximity to vascular accidents that merely reflects an adverse risk factor pattern, recent evidence suggests that uric acid may be deleterious to the brain rather than protective [5,8,39–42]. Given that the presence of CBMs portends an increased risk of ICH our study suggests another detrimental role of uric acid as a potential ICH risk factor.

Author Contributions

Conceived and designed the experiments: WSR SHL. Performed the experiments: BJK CKK. Analyzed the data: WSR. Contributed reagents/materials/analysis tools: SHL. Wrote the paper: WSR SHL.

References

1. Dimitroula HV, Hatzitolios AI, Karvounis HI (2008) The role of uric acid in stroke: the issue remains unresolved. Neurologist 14: 230–242.
2. Becker BF (1993) Towards the physiological function of uric acid. Free Radic Biol Med 14: 615–631.
3. Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP (1998) Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 53: 613–625.
4. Schelten DJ, Inscoe AB, Vannorsdall TD, Krant M, Pearson GD, et al. (2007) Serum uric acid and brain ischemia in normal elderly adults. Neurology 69: 1418–1423.
5. Bos MJ, Koudstaal PJ, Hofman A, Wittman JC, Breteler MM (2006) Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 37: 1503–1507.
6. Anker SD, Doehner W, Rauchhau M, Sharma R, Francis D, et al. (2005) Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107: 1991–1997.
Uric Acid and Cerebral Microbleeds

7. Lise AD, Hense HW, Lowel H, Doring A, Tietze M, et al. (1999) Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology 10: 391–397.

8. Karagiannis A, Mikhaidedis DP, Tsionalos K, Sileli M, Savvatianos S, et al. (2007) Serum uric acid as an independent predictor of early death after acute stroke. Circ J 71: 1120–1127.

9. Renavarte O, White GL, Roldan AM (2005) Small vessel strokes. Curr Cardiol Rep 7: 23–28.

10. Smith EE (2010) Leukoaraiosis and stroke. Stroke 41: S139–143.

11. Lee SH, Ryu WS, Roh JK (2009) Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. Neurology 72: 171–176.

12. van den Boom R, Bornehrook M, Behlou F, van den Berg-Huysmans AA, Haan J, et al. (2005) Microbleeds in hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neurology 64: 1289–1297.

13. Lee SH, Bae HJ, Kwon SJ, Kim H, Kim YH, et al. (2004) Cerebral microbleeds are regionally associated with intracerebral hemorrhage. Neurology 62: 72–76.

14. Fito M, Biosca C, Hernandez JM, Galimany R (1997) Potential interfering substances on Falcor-600 and Dax-68 analytical systems. Eur J Clin Chem Clin Biochem 35: 787–792.

15. (2006) KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47: S1–145.

16. Vernooy MW, van der Lugt A, Ikram MA, Wielopolski PA, Nielsen WJ, et al. (2008) Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology 70: 1208–1214.

17. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA (1987) MR signal intensity in white matter of the elderly: a study of normal aging. AJNR Am J Roentgenol 149: 551–556.

18. Greenberg SM, Vernooy MW, Cordnionier C, Viswanathan A, Al-Shahi Salman R, et al. (2009) Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 8: 163–174.

19. Lee SH, Park JM, Kwon SJ, Kim H, Kim YH, et al. (2004) Left ventricular hypertrophy is associated with cerebral microbleeds in hypertensive patients. Neurology 63: 16–21.

20. Quo C, Cotch MF, Sigurdsson S, Jonsson PV, Jonsdottir MK, et al. (2010) Cerebral microbleeds, retinopathy, and dementia: the AGES-Reykjavik Study. Neurology 75: 16–21.

21. Cho AH, Lee SB, Han SJ, Shon YM, Yang DW, et al. (2009) Impaired kidney function and cerebral microbleeds in patients with acute ischemic stroke. Neurology 73: 1645–1648.

22. Mazzali M, Kanelis J, Han L, Feng L, Xia YY, et al. (2002) Hyperuricemia induces a primary renal arteriopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282: F991–997.

23. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, et al. (2003) Uric acid stimulates monocyte chemotactic protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41: 1207–1293.

24. Rao GN, Corson MA, Berk BC (1991) Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 266: 8604–8608.

25. Langloin M, De Bacquer D, Duprez D, De Buyzere M, Delanghe J, et al. (2003) Serum uric acid in hypertensive patients with and without peripheral arterial disease. Atherosclerosis 168: 163–168.

26. Broughton Pipkin F (2004) Uric acid, endothelial dysfunction and pre-eclampsia. J Hypertens 22: 237–239.

27. Patellas P, Song M, Shutzer WP, Pappas C, Rodino W, et al. (2001) Identification of uric acid and xanthine oxidase in atherosclerotic plaque. Am J Cardiol 88: 19–1, A106.

28. Colletton RF, Larson MG, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131: 7–13.

29. Koemoeke HC (2006) Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology 66: 163–171.

30. Kim DE, Bae HJ, Lee SH, Kim H, Yoon BW, et al. (2002) Gradient echo magnetic resonance imaging in the prediction of hemorrhagic vs ischemic stroke: a need for the consideration of the extent of leukoaraiosis. Arch Neurol 59: 425–429.

31. Tanaka A, Ueno Y, Nakayama Y, Takano K, Takebayashi S (1999) Small chronic hemorrhages and ischemic lesions in association with spontaneous intracerebral hematomas. Stroke 30: 1637–1642.

32. Ueno H, Naka H, Ohshita T, Kondo K, Nomura E, et al. (2008) Association between cerebral microbleeds on T2* weighted MR images and recurrent hemorrhagic stroke in patients treated with warfarin following ischemic stroke. AJNR Am J Neuroradiol 29: 1483–1486.

33. Lee SH, Kim BJ, Roh JK (2006) Silent microbleeds are associated with volume of primary intracerebral hemorrhage. Neurology 66: 430–432.

34. Derex L, Nighoghossian N (2008) Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry 79: 1059–1099.

35. Wardlaw JM, Ferguson KJ, Graham C (2004) White matter hyperintensities and rating scales-observer reliability varies with lesion load. J Neurol 251: 584–590.

36. Britton M, Carlson A, de la Faire U (1986) Blood pressure course in patients with acute stroke is related to the severity of the neurological deficits. Acta Neurol Scandinav 106: 142–147.

37. Christensen H, Meden P, Overgaard K, Boysen G (2002) The course of blood pressure in acute stroke is related to the severity of the neurological deficits. Acta Neurol Scand 106: 142–147.

38. Jeon SB, Kwon SU, Cho AH, Yun SC, Kim JS, et al. (2009) Rapid appearance of new cerebral microbleeds after acute ischemic stroke. Neurology 73: 1638–1644.

39. Amaro S, Planas AM, Chamorro A (2008) Uric acid administration in patients with acute stroke: a novel approach to neuroprotection. Expert Rev Neurother 8: 259–270.

40. Haberman F, Tang SC, Arumugam TV, Hyun DH, Yu QS, et al. (2007) Soluble neuroprotective antioxidant uric acid analogs ameliorate ischemic brain injury in mice. Neurumolecular Med 9: 315–323.

41. Chamorro A, Planas AM, Munoz DS, Deulofeu R (2004) Uric acid administration for neuroprotection in patients with acute brain ischemia. Med Hypotheses 62: 173–176.

42. Hozawa A, Folsom AR, Ibrahim H, Javier Nieto F, Rosamond WD, et al. (2006) Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis 187: 401–407.